According to Stirling Products, the company is in discussions with several major pharmaceutical companies about partnerships on products using its patented high density aerosol (HDA) device. The company says that its ultrasound-based HDA technology produces a concentration level three times higher than that of other ultrasonic devices. One version of the device has 510(k) approval, and Stirling says that it is developing more advanced versions. Read the company’s press release.
